Abcellera to collaborate with biogen to discover therapeutic antibodies for neurological conditions

Vancouver, british columbia--(business wire)---- $abcl--abcellera (nasdaq: abcl) and biogen inc. (nasdaq: biib) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience. “delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience,” said murray mccutcheon, ph.d., svp, partnering at abcellera. “we are excited to work with bio.
ABCL Ratings Summary
ABCL Quant Ranking